ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Lexicon Pharmaceuticals, Inc. (LXRX) stock declined over -11.91%, trading at $0.44 on NASDAQ, down from the previous close of $0.50. The stock opened at $0.48, fluctuating between $0.44 and $0.51 in the recent session.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Employees | 103 |
Beta | 1.05 |
Sales or Revenue | $1.20M |
5Y Sales Change% | -0.991% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |